Related Experiment Video
Updated: Jan 10, 2026
Modification and Functionalization of the Guanidine Group by Tailor-made Precursors
Published on: April 27, 2017
Conjugating 10,11-Dimethoxy-camptothecin with an Integrin αvβ3-Targeting Peptide through a Triazine Linker for
Chaoming Wang1,2, Jing Zhang1, Dongping Wang1
1Key Laboratory of Marine Drugs Chinese Ministry of Education, Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, PR China.
Abstract:
Peptide-drug conjugates (PDCs) targeting integrin αvβ3 represent a promising strategy for tumor-targeted therapies. We designed and synthesized a series of integrin αvβ3-selective PDCs (PDC-1 to PDC-5) using a 1,3,5-triazine-based linker to conjugate the camptothecin derivative with the c(RGDfC) peptide. Among these, PDC-2 exhibited high stability in plasma, selective internalization via integrin αvβ3, efficient cell binding, and potent cytotoxicity. Additionally, it induced apoptosis of A549 and AsPC-1 cells and inhibited their adhesion, migration, and invasion in a concentration-dependent manner. Mechanistically, PDC-2 dually inhibits Survivin protein expression and the PI3K/AKT/mTOR signaling pathway. In A549 and AsPC-1 xenograft models, PDC-2 demonstrated superior tumor growth inhibition, reduced systemic toxicity, and enhanced tumor specificity compared to FL118. Pharmacokinetically, it enabled a sustained release of FL118, extending its half-life by 3.4-fold and promoting targeted tumor accumulation, positioning it as a promising therapeutic for lung and pancreatic cancers.
Insights
New peptide-drug conjugates (PDCs) targeting integrin αvβ3 show promise for cancer therapy. PDC-2 demonstrated potent anti-cancer effects, reduced toxicity, and enhanced tumor targeting in preclinical models.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Background:
- Integrin αvβ3 is a key target for anti-cancer drug development.
- Peptide-drug conjugates (PDCs) offer a strategy for targeted cancer therapy.
- Developing PDCs with improved stability and efficacy is crucial.
Purpose of the Study:
- To design and synthesize novel integrin αvβ3-selective PDCs.
- To evaluate the anti-cancer efficacy and mechanism of action of these PDCs.
- To assess the therapeutic potential of the lead PDC in preclinical cancer models.
Main Methods:
- Synthesis of a series of PDCs (PDC-1 to PDC-5) using a 1,3,5-triazine linker.
- In vitro evaluation of cell binding, internalization, cytotoxicity, apoptosis, adhesion, migration, and invasion.
- In vivo studies using A549 and AsPC-1 xenograft models.
- Pharmacokinetic analysis of PDC-2.
Main Results:
- PDC-2 showed high plasma stability, selective integrin αvβ3 internalization, and potent cytotoxicity.
- PDC-2 induced apoptosis and inhibited cancer cell migration and invasion.
- PDC-2 demonstrated superior tumor growth inhibition and reduced toxicity compared to FL118 in vivo.
- PDC-2 exhibited sustained drug release and enhanced tumor accumulation.
Conclusions:
- PDC-2 is a highly effective integrin αvβ3-targeted PDC with dual inhibition of Survivin and PI3K/AKT/mTOR signaling.
- PDC-2 shows significant therapeutic potential for lung and pancreatic cancers with improved safety and efficacy profiles.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
01:15Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...